





# USES OF EVERNOA TECHNOLOGY

Evernoa technology could be useful to face various aspects in clinical trials and post-market surveillance trials


## FeNO for treatments under study: Phase II and phase III

**1. Efficacy assessment:** The evolution of FeNO over the time assess if airway inflammation is subsiding





**2. Patient phenotyping - Biomarkers for patient selection:** FeNO could be used as a biomarker useful to determine potential responsive patients.


**3. Reaching distal airway.** CalvNo can determine if medication is reaching distal airway and if alveolar inflammation is subsiding.



CalvNO Increased: alveolar inflammation  
CawNO Increased: Bronchi inflammation





CalvNO Low: NO alveolar inflammation  
CawNO Increased: Bronchi inflammation



## FeNO for post-market surveillance: phase IV

**1. Treatment adherence.** New administration forms increase adherence?



**2. Exacerbations characterization.** Determine exacerbations based on an objective biomarker rather than on clinical symptoms described by patients

**3. Real time guiding of inhaler.** Information concerning the correct use of inhalers could be provided by evernoa SW

**4. Prevention of overmedication.** FeNO can guide the clinician to adjust the dose to the required minimum

